Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Dementia01:30

Dementia

94
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
94

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autonomous biomedical research with an artificial intelligence agent.

Science (New York, N.Y.)·2026
Same author

Proteomic profiling reveals ACTN1-mediated cytoskeletal remodelling and hyperplasia of cerebrovascular smooth muscle cells in moyamoya disease.

Clinical and translational medicine·2026
Same author

Steric Coordination Modulated Iodine Chemistry With Four-Electron Conversion for Zinc-Iodine Batteries.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

The Sunlight-7 Framework: an optics-inspired approach to accelerating Sustainable Development Goals.

Science bulletin·2026
Same author

Ion-Sieving Dual-Scale Asymmetric Cellulose Membrane as a Sustainable Paper-Based Separator for Ultra-Stable Zinc Anodes.

Nano-micro letters·2026
Same author

Cellulose-based ultralight foam with dual-scale porosity from hybrid fibers for sustainable oil-water separation.

Carbohydrate polymers·2026

Related Experiment Video

Updated: Jun 4, 2025

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

2.9K

Cognitive dysfunction in Moyamoya disease: latest developments and future directions.

Xilong Wang1, Ziqi Liu1, Zhenyu Zhou1

  • 1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

Frontiers in Human Neuroscience
|December 23, 2024
PubMed
Summary

Moyamoya disease (MMD) commonly causes cognitive dysfunction, affecting memory and executive functions. More research is needed to understand MMD

Keywords:
Moyamoya diseasecognitive functioncognitive impairmentneuropsychologyrevascularization

More Related Videos

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

2.7K
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:19

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

400

Related Experiment Videos

Last Updated: Jun 4, 2025

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

2.9K
A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice
06:54

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

2.7K
A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis
05:19

A Mouse Model for Vascular Cognitive Impairment and Dementia Based on Needle-guided Asymmetric Bilateral Common Carotid Artery Stenosis

Published on: November 22, 2024

400

Area of Science:

  • Neuroscience
  • Neurology
  • Medical Research

Background:

  • Cognitive dysfunction is a frequent complication of Moyamoya disease (MMD).
  • Existing knowledge regarding cognitive impairment in MMD is insufficient.
  • MMD affects various cognitive domains, including executive function, intelligence, and memory.

Purpose of the Study:

  • To review the characteristics of cognitive function alterations in MMD.
  • To provide recommendations for future research on MMD-related cognitive dysfunction.

Main Methods:

  • Literature review of studies on cognitive function in Moyamoya disease.
  • Analysis of cognitive deficits reported in MMD patients.
  • Synthesis of current understanding and identification of research gaps.

Main Results:

  • MMD is associated with characteristic declines in executive function, intelligence, and memory.
  • The impact of cerebral revascularization surgery on cognitive impairment in MMD remains controversial.
  • There is a significant lack of comprehensive research on cognitive impairment in MMD.

Conclusions:

  • Cognitive dysfunction is a key feature of Moyamoya disease, necessitating further investigation.
  • Future research should focus on the pathogenesis, etiology, and long-term cohort studies of MMD.
  • Understanding and addressing cognitive impairment in MMD is crucial for patient care and management.